<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>阿斯利康（AstraZeneca）的COVID-19疫苗显示出了成功：这就是它如何与其他药物叠加AstraZeneca’s COVID-19 vaccine shows success: Here’s how it stacks up to others</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">AstraZeneca’s COVID-19 vaccine shows success: Here’s how it stacks up to others<br/>阿斯利康（AstraZeneca）的COVID-19疫苗显示出了成功：这就是它如何与其他药物叠加</h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2020-11-24 02:48:38</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2020/11/4456753d139ecb111492fd59877b7e3f.jpg"><img src="http://img2.diglog.com/img/2020/11/4456753d139ecb111492fd59877b7e3f.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>AstraZeneca announced in  a press release on Monday that its COVID-19 vaccine showed positive results in an interim analysis of clinical trial data.</p><p>阿斯利康周一在新闻稿中宣布，其COVID-19疫苗在临床试验数据的中期分析中显示出积极结果。</p><p> The announcement marks the third vaccine to show strong efficacy in late-stage trials against the pandemic coronavirus, SARS-CoV-2. Though AstraZeneca’s vaccine efficacy numbers are not as impressively high as those for the vaccines before it—mRNA vaccines from  Pfizer/BioNTech and  Moderna—AstraZeneca&#39;s does offer some advantages over those vaccines.</p><p> 该公告标志着第三种疫苗在后期试验中显示出针对大流行性冠状病毒SARS-CoV-2的强大功效。尽管阿斯利康的疫苗功效数字不及之前的疫苗（辉瑞/ BioNTech和Moderna的mRNA疫苗）高，但阿斯利康的确比这些疫苗具有一些优势。</p><p> In all, the news adds to ballooning optimism that effective vaccines could bring an end to the global crisis in the coming year.</p><p> 总而言之，这一消息使人们更加乐观，即有效的疫苗可以在来年终结全球危机。</p><p>  AstraZeneca partnered with researchers at the University of Oxford to develop the  viral vector-based vaccine called  AZD1222 (also called ChAdOx1 nCoV-19). The vaccine involves having genetic material coding for the notorious SARS-CoV-2 spike protein carried into the body by a relatively benign virus. In this case, the virus is a weakened type of adenovirus—a pathogen that can cause common colds and other mild infections in humans and some animals. The adenovirus used is one that mainly infects chimpanzees. When the adenovirus package delivers the code for the SARS-CoV-2 spike protein, the immune system can then train itself to recognize and destroy anything with the same spike protein—and that would be all SARS-CoV-2 viral particles, which are studded with spike proteins.</p><p>  阿斯利康与牛津大学的研究人员合作开发了基于病毒载体的疫苗，称为AZD1222（也称为ChAdOx1 nCoV-19）。该疫苗涉及具有遗传材料，该遗传材料编码由相对温和的病毒带入体内的臭名昭著的SARS-CoV-2穗突蛋白。在这种情况下，该病毒是腺病毒的一种弱化类型-一种可引起人类和某些动物普通感冒和其他轻度感染的病原体。所用的腺病毒是主要感染黑猩猩的一种。当腺病毒包提供SARS-CoV-2穗蛋白的代码时，免疫系统可以训练自己识别并破坏具有相同穗蛋白的任何东西-那就是所有SARS-CoV-2病毒颗粒，它们是散布着刺突蛋白。</p><p> The AZD1222 results announced today come from a pooled analysis of clinical trials conducted in the United Kingdom and Brazil, involving over 23,000 participants. AstraZeneca’s independent monitoring board found AZD1222 was on average about 70-percent effective at preventing COVID-19, the disease caused by SARS-CoV-2. The interim analysis was triggered when 131 cases showed up in participants across the trials, who were given either two doses of AZD1222 or a comparator vaccine, the meningococcal vaccine MenACWY. The efficacy rate is calculated based on how those 131 cases split into the MenACWY group versus the AZD1222 group.</p><p> 今天公布的AZD1222结果来自对英国和巴西进行的临床试验的汇总分析，涉及23,000多名参与者。阿斯利康的独立监测委员会发现，AZD1222在预防COVID-19（由SARS-CoV-2引起的疾病）方面平均有效率为70％。当在整个试验中有131例参与者出现时，即进行了中期分析，他们被给予了两剂AZD1222或比较疫苗，即脑膜炎球菌疫苗MenACWY。根据这131例患者分为MenACWY组和AZD1222组的方式计算出有效率。</p><p> But the results were a little more complicated than that simple split. Participants who received AZD1222 got one of two dosing regimens, so the results were split further. In one regimen, participants were given a half-dose of AZD1222 followed by a booster shot with a full dose. In the trials, 2,741 participants got this regimen, and it appeared about 90-percent effective at preventing COVID-19.</p><p> 但是结果要比简单的拆分复杂得多。接受AZD1222的参与者获得了两种给药方案之一，因此结果进一步分开。在一种方案中，给参与者半剂量的AZD1222，然后以全剂量进行加强注射。在试验中，有2,741名参与者采用了该方案，并且在预防COVID-19方面似乎有90％的有效率。</p><p> In the other regimen, participants receiving AZD1222 got two full doses of the vaccine. In other words, they got the same high dosage level in their first shot as in their booster shot. In the trials, 8,895 participants got this regimen, and it appeared about 62-percent effective at preventing COVID-19.</p><p> 在另一种方案中，接受AZD1222的参与者获得了两剂完整剂量的疫苗。换句话说，他们在第一次注射时的剂量水平与加强注射时相同。在试验中，有8,895名参与者采用了该方案，并且在预防COVID-19方面似乎有62％的有效率。</p><p>    The pooled efficacy data yields the average efficacy at around 70 percent. This is impressive, given a goal of around 50 percent. However, it’s not quite as high as the stunning mRNA vaccine efficacy results reported in previous weeks. Those included  95 percent efficacy for Pfizer/BioNTech’s vaccine and  94.5 percent efficacy for Moderna’s.</p><p>汇总的功效数据得出的平均功效约为70％。鉴于目标约为50％，这令人印象深刻。但是，它不如前几周报道的惊人的mRNA疫苗功效结果高。其中包括辉瑞/ BioNTech疫苗的95％功效和Moderna疫苗的94.5％功效。</p><p>  AstraZeneca’s better result with the regimen starting with a half dose has already led to head scratching among experts. Most importantly, it’s unclear if the 90-percent efficacy result will hold up as AstraZeneca collects more data and conducts further analyses. We don’t yet know how the 131 cases split in the subgroup analyses. That final efficacy number is very likely to change as more data is collected. But, if that finding does hold up, some experts have already begun speculating as to why.</p><p>  从半剂量开始的阿斯利康方案的更好效果已经导致专家们head不休。最重要的是，随着阿斯利康收集更多数据并进行进一步分析，尚不清楚90％的疗效结果能否持久。我们尚不清楚这131个案例在子组分析中是如何划分的。随着收集更多数据，最终功效数字很可能会发生变化。但是，如果这一发现确实成立，那么一些专家已经开始猜测原因。</p><p> Several think it may be down to the adenovirus packaging. Though the vaccine is aimed at spurring immune responses against the SARS-CoV-2 spike protein carried by the adenovirus, some immune responses will inevitably attack the adenovirus itself. If the two-dose regimen starts out high, it may tip the immunity scales toward a stronger anti-adenovirus response rather than an anti-spike response when the booster shot is delivered. This is speculative, though, and understanding what&#39;s actually happening will require far more data.</p><p> 一些人认为这可能归结于腺病毒的包装。尽管该疫苗旨在激发针对腺病毒携带的SARS-CoV-2突突蛋白的免疫反应，但某些免疫反应不可避免地会攻击腺病毒本身。如果两剂治疗方案从高剂量开始，则在加强注射时，免疫力可能会朝着更强的抗腺病毒反应而不是抗尖峰反应的方向发展。但是，这只是推测性的，要了解实际发生的情况将需要更多的数据。</p><p> On a positive note, needing less vaccine in the first dose—if that really does end up being the case—means more people can be vaccinated with the same amount of vaccine manufacturing capacity.</p><p> 积极的一点是，如果确实如此，那么第一剂量就需要较少的疫苗，这意味着可以用相同数量的疫苗生产能力为更多的人接种疫苗。</p><p> And on yet another positive—though very preliminary—note, the Oxford researchers reported that AZD1222 appeared to reduce asymptomatic infections with SARS-CoV-2. The primary analysis looked at symptomatic cases of COVID-19, but some participants in the trial were regularly screened for asymptomatic infection. This finding is particularly eyebrow-raising since the mRNA vaccine trials exclusively looked at only symptomatic COVID-19 cases. However, the finding is extremely preliminary as the researchers did not present any data on it.</p><p> 牛津大学的研究人员在另一个积极的（虽然非常初步的）说明上报告说，AZD1222似乎可以减少SARS-CoV-2的无症状感染。初步分析着眼于有症状的COVID-19病例，但该试验的一些参与者定期接受了无症状感染的筛查。由于mRNA疫苗试验仅针对有症状的COVID-19病例，因此这一发现尤其令人震惊。但是，这一发现是非常初步的，因为研究人员没有提供任何数据。</p><p>  As with the mRNA vaccines, AstraZeneca said no serious adverse events related to the vaccine “have been confirmed.” In earlier trial results, mild side effects from AZD1222 were common, including pain, feeling feverish, chills, muscle ache, headache, and malaise. Some participants were preemptively given paracetamol (acetaminophen/Tylenol) to lessen these effects.</p><p>  与mRNA疫苗一样，阿斯利康表示“尚未确认与疫苗相关的严重不良事件。”在较早的试验结果中，AZD1222的轻度副作用是常见的，包括疼痛，发烧，发冷，肌肉疼痛，头痛和全身不适。为减轻这些影响，一些参与者被抢先服用了扑热息痛（对乙酰氨基酚/甲苯酚）。</p><p> If you’ll recall, AstraZeneca  paused its trials at least twice, once in July and another in September, for standard safety reviews. Trials paused in July when a UK participant showed neurological symptoms and was later diagnosed with multiple sclerosis. In September, another participant developed symptoms in line with transverse myelitis—a condition involving inflammation of the spinal cord that can, in rare instances, be linked to vaccination. Both cases were eventually dubbed unrelated to the vaccine itself and the trials resumed.</p><p> 您可能还记得，阿斯利康（AstraZeneca）至少两次暂停了试验，分别于7月和9月暂停了一次，以进行标准安全性审查。 7月，当一名英国参与者出现神经系统症状并随后被诊断出患有多发性硬化症时，试验暂停。在9月，另一名参与者出现了与横纹肌炎相适应的症状-这种疾病涉及脊髓发炎，在极少数情况下，可与疫苗接种有关。最终，这两个病例都被冠以与疫苗本身无关的称号，并继续进行试验。</p><p>      A significant advantage to AstraZeneca’s adenovirus vaccine is that it is relatively easy to scale up production and doesn’t require specialized storage conditions. Adenovirus vectors are more established in the vaccine arena, compared with mRNA-based vaccines, which are brand-new. Manufacturing capacity to produce vast quantities of adenovirus already exists.</p><p>阿斯利康腺病毒疫苗的一个显着优势是它相对容易扩大规模，并且不需要专门的存储条件。与基于mRNA的新型疫苗相比，腺病毒载体在疫苗领域的地位更为明显。生产大量腺病毒的生产能力已经存在。</p><p> AstraZeneca noted in its press release that it is “making rapid progress in manufacturing with a capacity of up to 3 billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval. The vaccine can be stored, transported and handled at normal refrigerated conditions (2-8 degrees Celsius/36-46 degrees Fahrenheit) for at least six months and administered within existing healthcare settings.”</p><p> 阿斯利康在其新闻稿中指出，“在制造方面取得了快速进展，到2021年，该产品的生产能力将滚动增长，达到30亿剂，尚待监管部门批准。该疫苗可以在正常冷藏条件（2-8摄氏度/ 36-46华氏度）下存储，运输和处理，至少可以保存六个月，并可以在现有的医疗机构内使用。”</p><p> The mRNA vaccines require cooler storage conditions. Most notably, Pfizer and BioNTech’s vaccine requires storage at a troublesome -70°C. In a recent press release, Pfizer emphasized that the companies “developed specially designed, temperature-controlled thermal shippers utilizing dry ice to maintain temperature conditions of -70°C ± 10°C. They can be used as temporary storage units for 15 days by refilling with dry ice.” The vaccine can further be stored at normal refrigerated 2-8°C conditions for five days.</p><p> mRNA疫苗需要较凉的储存条件。最值得注意的是，辉瑞和BioNTech的疫苗需要在麻烦的-70°C下储存。辉瑞公司在最近的新闻稿中强调，这些公司“开发了专门设计的，温度控制的热运输船，利用干冰将其保持在-70°C±10°C的温度条件下。通过装满干冰，它们可以用作临时存储单元15天。”疫苗可进一步在2-8°C的正常冷藏条件下保存5天。</p><p> Pfizer and BioNTech are aiming to have up to 50 million vaccine doses in 2020 globally and up to 1.3 billion doses by the end of 2021.</p><p> 辉瑞和BioNTech的目标是到2020年在全球范围内接种5000万剂疫苗，到2021年底达到13亿剂。</p><p> Moderna announced in  a recent press release that its vaccine remains stable for six months at -20° C (-4°F), up to 30 days at normal refrigerator temperature (2-8 degrees C or 36-46 degrees F), and up to 12 hours at room temperature. Moderna currently plans to have about 20 million doses of mRNA-1273 ready to ship in the US in 2020 and produce an additional 500 million to 1 billion doses globally in 2021.</p><p> Moderna在最近的新闻稿中宣布，其疫苗在-20°C（-4°F）的温度下可稳定稳定六个月，在正常冰箱温度（2-8摄氏度或36-46华氏度）下可长达30天，并且在室温下长达12小时。 Moderna目前计划在2020年准备将约2000万剂mRNA-1273运往美国，并于2021年在全球再生产5亿至10亿剂。</p><p> All three vaccines are now headed to regulators worldwide for authorization. Pfizer submitted  its request for an Emergency Use Authorization from the US Food and Drug Administration on Friday.</p><p> 所有这三种疫苗现在都将前往全球监管机构进行授权。辉瑞公司于周五提交了美国食品和药物管理局的紧急使用授权请求。</p><p>  All three vaccines have yet to have their full datasets published, so much uncertainty remains about the data and analyses. The efficacy numbers will likely change as trials continue, safety monitoring grows longer, and peer reviewers look over the analyses. Rare side effects are also more likely to pop up as time goes on.</p><p>  这三种疫苗尚未公布其完整的数据集，因此数据和分析仍存在很多不确定性。随着试验的继续，安全性监测时间的延长以及同行评审员对分析的关注，功效数字可能会发生变化。随着时间的流逝，罕见的副作用也更有可能弹出。</p><p> While preliminary studies on the vaccines suggested they all prompt a variety of immune responses in participants, how long any protection from any of these vaccines may last is completely unknown. It&#39;s still unclear what levels of immune responses equate to full protection from an infection or severe disease. And in a one-year-old pandemic with a completely new-to-us pathogen, it’s impossible to say with certainty how long those protective immune responses will stay protective.</p><p>尽管对疫苗的初步研究表明它们都能促使参与者产生多种免疫反应，但对这些疫苗的任何保护作用能持续多长时间完全未知。尚不清楚什么水平的免疫应答等同于对感染或严重疾病的全面保护。而且，在一岁的大流行病中，病原体是全新的，因此无法确定地说这些保护性免疫反应将保持保护性的时间。</p><p> Last, there’s so far no data on how well the vaccines protect against asymptomatic infections. Preventing disease—and in particular, life-threatening disease—is the top priority in these trials. However, preventing asymptomatic or mild infections will be key to putting an end to SARS-CoV-2 transmission overall.</p><p> 最后，到目前为止，尚无有关疫苗对无症状感染的防护效果的数据。在这些试验中，预防疾病（尤其是威胁生命的疾病）是重中之重。但是，预防无症状或轻度感染将是全面终止SARS-CoV-2传播的关键。</p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://arstechnica.com/science/2020/11/astrazenecas-covid-19-vaccine-shows-success-heres-how-it-stacks-up-to-others/">https://arstechnica.com/science/2020/11/astrazenecas-covid-19-vaccine-shows-success-heres-how-it-stacks-up-to-others/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/shows/">#shows</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/疫苗/">#疫苗</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>